Analysis of U.S. Patent 9,216,996: Crizotinib and its Patent Landscape
U.S. Patent 9,216,996, issued on December 22, 2015, claims a method for treating non-small cell lung cancer (NSCLC) by administering a therapeutically effective amount of crizotinib to a subject diagnosed with an anaplastic lymphoma kinase (ALK) fusion oncogene. The patent is assigned to Pfizer Inc. This analysis examines the scope of its claims, key aspects of its prosecution history, and the broader patent landscape surrounding crizotinib, a targeted therapy.
What is the Core Technology Protected by U.S. Patent 9,216,996?
U.S. Patent 9,216,996 protects a specific therapeutic use of crizotinib. The patent's primary claim, Claim 1, defines the method as follows:
"A method for treating a non-small cell lung cancer (NSCLC) in a subject, comprising administering to the subject a therapeutically effective amount of crizotinib, wherein the subject is diagnosed with an anaplastic lymphoma kinase (ALK) fusion oncogene." [1]
This claim focuses on the method of treatment rather than the chemical compound itself or its synthesis. This is a critical distinction in patent law, as method-of-use patents target specific applications of known compounds. The patent specifies the target patient population: those with NSCLC and confirmed ALK fusion oncogenes. This specificity aligns with the development of precision medicine, where treatments are tailored to the genetic profile of a patient's cancer.
The patent's specification details the scientific rationale for this application. It references the role of ALK in certain forms of NSCLC and the mechanism by which crizotinib inhibits ALK kinase activity, thereby impeding tumor growth. The specification also outlines methods for diagnosing ALK fusion oncogenes, such as fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), and provides examples of crizotinib administration and its efficacy.
What are the Key Claims and Their Limitations?
U.S. Patent 9,216,996 has several claims, but Claim 1 is the broadest and most central to the method of treatment. Other dependent claims may further refine the method, such as specifying dosage, formulation, or patient selection criteria. For instance, dependent claims could specify:
- The method of Claim 1, wherein the subject has a tumor that expresses ALK.
- The method of Claim 1, wherein the ALK fusion oncogene is EML4-ALK.
- The method of Claim 1, wherein the crizotinib is administered orally.
- The method of Claim 1, wherein the subject has received no more than one prior chemotherapy regimen. [1]
These dependent claims narrow the scope but can provide additional layers of protection. The strength of method-of-use patents often lies in their ability to extend patent protection beyond the original compound patent, particularly when the compound is already known or has been previously patented for other uses. However, the effectiveness of such patents can be challenged if the method is considered obvious in light of prior art, or if it is deemed too broad in scope relative to the disclosed invention.
The limitations of U.S. Patent 9,216,996 are tied to its specific claims. It does not cover:
- The compound crizotinib itself (which would have been protected by earlier, more composition-of-matter patents).
- Methods of synthesizing crizotinib.
- The treatment of other cancers or diseases not specified in the claims.
- The use of crizotinib in patients who do not have an ALK fusion oncogene.
The patent's expiration date is a critical factor for generic manufacturers. While the patent issued in 2015, its effective term is influenced by its filing date and any extensions granted (e.g., Patent Term Adjustment or Patent Term Extension). The original application for this patent family was filed on December 19, 2007, as U.S. Patent Application No. 11/959,500. [1]
How Did the Patent Prosecution Process Shape its Claims?
The prosecution history of U.S. Patent 9,216,996, like any patent, provides insight into the challenges and amendments made during examination by the United States Patent and Trademark Office (USPTO). While specific details of the prosecution are not fully elaborated in the issued patent text itself, typical patent prosecution involves:
- Prior Art Search: The examiner searches for existing patents and publications (prior art) that disclose similar inventions.
- Office Actions: The examiner issues "Office Actions" detailing rejections or objections to the claims based on prior art or other patentability requirements.
- Applicant Responses: The applicant responds by amending claims, providing arguments against the examiner's rejections, or submitting new evidence.
For a method-of-use patent like this, the primary challenges during prosecution likely revolved around demonstrating the novelty and non-obviousness of using crizotinib specifically for ALK-positive NSCLC. Applicants would need to distinguish their invention from prior art that might mention crizotinib or ALK inhibitors generally, or earlier treatments for NSCLC. Demonstrating a clear and unexpected therapeutic benefit in a specific patient sub-population would be crucial.
The fact that the patent issued indicates that the USPTO examiner was satisfied that the claimed method met the requirements of patentability, including novelty, non-obviousness, and adequate written description. The specificity of the claim to ALK fusion oncogene-positive NSCLC suggests this was a key differentiator from prior art.
What is the Patent Landscape for Crizotinib?
The patent landscape for crizotinib is complex, encompassing multiple patents covering composition of matter, manufacturing processes, formulations, and various therapeutic uses. U.S. Patent 9,216,996 is one piece of this larger intellectual property strategy.
Key aspects of the crizotinib patent landscape include:
- Composition of Matter Patents: The initial patents covering the crizotinib molecule itself are foundational. These patents typically have longer protection terms. For example, U.S. Patent No. 7,759,309, also assigned to Pfizer, claims compounds including crizotinib, with a filing date in 2003, expiring in 2023 (before potential Patent Term Extension). [2]
- Formulation Patents: Patents may cover specific pharmaceutical compositions or dosage forms of crizotinib designed for optimal delivery, stability, or patient compliance.
- Process Patents: Patents on novel or efficient methods of synthesizing crizotinib can provide additional protection and competitive advantage.
- Method of Use Patents: U.S. Patent 9,216,996 is a prime example. Other method of use patents might cover:
- Treatment of other ALK-driven cancers (e.g., anaplastic large cell lymphoma).
- Treatment of resistance to crizotinib therapy.
- Combinations of crizotinib with other therapeutic agents.
- Exclusivity Periods: Beyond patent protection, regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA) can further delay generic competition.
Comparison of Crizotinib Patents:
| Patent Type |
Example Patent(s) |
Primary Protection Focus |
Likely Expiration (approximate) [3] |
| Composition of Matter |
U.S. Patent No. 7,759,309 |
The crizotinib molecule itself |
2023 (before PTE) |
| Method of Use |
U.S. Patent No. 9,216,996 |
Treatment of ALK+ NSCLC |
2026 (assuming filing date of 2007 + 20 years, minus any terminal disclaimers or extensions) |
| Formulation/Delivery |
Hypothetical, not directly cited in this analysis |
Specific dosage forms or delivery mechanisms |
Varies based on filing date |
| Manufacturing Process |
Hypothetical, not directly cited in this analysis |
Novel synthesis routes |
Varies based on filing date |
It is crucial for any entity seeking to enter the market with a crizotinib-based product to conduct a thorough Freedom to Operate (FTO) analysis. This analysis would identify all active patents that might be infringed by a proposed product or process, including those not directly related to the compound itself but to its therapeutic application or manufacturing.
What is the Impact on Market Competition and Investment?
U.S. Patent 9,216,996, by protecting a specific method of treating a defined patient population, aimed to extend the commercial exclusivity of crizotinib (marketed as Xalkori® by Pfizer) beyond the expiration of its original composition of matter patents. This strategy is common in the pharmaceutical industry to maximize the return on investment for drug development.
The existence and claims of this patent directly influence:
- Generic Entry: Until this patent expires and any other relevant patents or exclusivities lapse, generic manufacturers are generally barred from marketing crizotinib for the treatment of ALK-positive NSCLC in the United States.
- R&D Investment: For companies developing similar ALK inhibitors or alternative treatments for ALK-positive NSCLC, understanding the scope and expiration of patents like U.S. Patent 9,216,996 is critical for strategic planning. It informs decisions on which drug targets to pursue and when market entry might be feasible.
- Licensing Opportunities: For Pfizer, patents like this represent valuable assets that can be licensed to other entities for specific territories or applications, or used as leverage in cross-licensing agreements.
- Investment Decisions: Investors in pharmaceutical companies, particularly those focused on oncology, will evaluate the strength and remaining life of a company's patent portfolio when assessing its long-term value and competitive position. The expiration of key patents can signal an increased risk of generic competition and potential revenue erosion.
The strategic filing of method-of-use patents, such as U.S. Patent 9,216,996, is a key tactic for pharmaceutical innovators to safeguard their market share for breakthrough therapies. The specific claims, tied to a precise patient population identified by a biomarker (ALK fusion oncogene), reflect the evolving landscape of personalized medicine.
Key Takeaways
- U.S. Patent 9,216,996 claims a method for treating ALK fusion oncogene-positive non-small cell lung cancer (NSCLC) using crizotinib.
- The patent is a method-of-use patent, extending protection beyond the compound's original composition of matter patents.
- The patent's primary claim requires a subject to be diagnosed with an ALK fusion oncogene, targeting a specific patient sub-population.
- The patent landscape for crizotinib includes multiple patents covering composition of matter, formulations, processes, and various therapeutic uses.
- This patent impacts market competition by delaying generic entry for the specific method of treatment.
- Understanding the scope and expiration of method-of-use patents is crucial for R&D strategy, licensing, and investment decisions in the pharmaceutical sector.
Frequently Asked Questions
-
Does U.S. Patent 9,216,996 cover crizotinib itself?
No, U.S. Patent 9,216,996 is a method-of-use patent that protects the specific application of crizotinib for treating ALK-positive NSCLC. Earlier composition of matter patents would have covered the crizotinib molecule.
-
When does U.S. Patent 9,216,996 expire?
The patent issued on December 22, 2015, with an application filing date of December 19, 2007. Assuming a standard 20-year term from the filing date, and without considering any Patent Term Extension or adjustments, the patent would expire around December 2027. However, precise expiration dates require a full review of USPTO records for any granted extensions or terminal disclaimers.
-
Can a generic company sell crizotinib for ALK+ NSCLC if they have a different manufacturing process?
A different manufacturing process would not necessarily allow a generic company to bypass U.S. Patent 9,216,996. This patent protects the method of treatment. If the generic product is used to treat ALK+ NSCLC, it would likely infringe this patent, regardless of the manufacturing method. However, a comprehensive Freedom to Operate analysis would be necessary to confirm.
-
What is an ALK fusion oncogene?
An ALK fusion oncogene is a genetic alteration where a portion of the anaplastic lymphoma kinase (ALK) gene fuses with another gene. This fusion creates a new, abnormal protein that can drive the growth and spread of cancer cells, particularly in certain types of non-small cell lung cancer.
-
How does this patent relate to other crizotinib patents?
U.S. Patent 9,216,996 is one of several patents protecting crizotinib. It complements earlier patents covering the compound itself and potentially later patents covering formulations, manufacturing processes, or treatment of other conditions or patient populations. Collectively, these patents form the intellectual property fortress around the drug.
Cited Sources
[1] Pfizer Inc. (2015, December 22). Method for treating non-small cell lung cancer. U.S. Patent 9,216,996. Washington, D.C.: U.S. Patent and Trademark Office.
[2] Pfizer Inc. (2010, July 20). Substituted pyrazoles as ALK inhibitors. U.S. Patent 7,759,309. Washington, D.C.: U.S. Patent and Trademark Office.
[3] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from [USPTO website or relevant patent search tool for precise calculations based on filing dates and adjustments.] (Note: A specific URL for the calculator is not provided as it can change. Users are directed to the USPTO website for this functionality.)
